Search Results
Long-term safety of niraparib maintenance treatment in patients with recurrent ovarian cancer
Niraparib Maintenance for Recurrent Ovarian Cancer
Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian Cancer
Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancer
PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023
Niraparib Maintenance Therapy for Ovarian Cancer
Jonathan A Ledermann – Maintenance Treatment for Recurrent Ovarian Carcinoma
Comment: Niraparib for ovarian cancer
PARP inhibitors as first-line maintenance therapy in ovarian cancer
Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian Cancer
New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer
Clinical Use of Niraparib in Ovarian Cancer
